What question did this study set out to answer?

To explore the association between immune-related adverse events and patient outcomes in non-small cell lung cancer.

February 22, 2026BMC Pulmonary Medicine0 citationsOpen Access

Impact of immune-related toxicity on survival and treatment response in non-small cell lung cancer patients

AVAlejandro Valcuende-RosiqueValencia Catholic University Saint Vincent Martyr CECorina Escoín-PérezHospital de La Ribera ASAgustín Sánchez-AlcarazHospital de La Ribera

Puntos clave

To explore the association between immune-related adverse events and patient outcomes in non-small cell lung cancer.
Analyzed data from NSCLC patients undergoing immune checkpoint inhibitor therapy.
Evaluated the presence of immune-related adverse events (irAEs).
Assessed treatment responses and overall survival rates.
Patients with irAEs showed improved survival rates compared to those without.
Enhanced treatment responses were noted in those experiencing irAEs.
Potential for irAEs to be used as predictive biomarkers for personalized treatment.

Resumen

The presence of irAEs is associated with enhanced survival and treatment response in NSCLC patients receiving ICIs. These findings underscore the potential of irAEs as predictive biomarkers, supporting personalized treatment strategies.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo